AstraZeneca's Calquence Combo Receives US FDA Approval for 1st-Line CLL Treatment

summarizeSummary

AstraZeneca's Calquence in combination with venetoclax has received US FDA approval as the first all-oral, fixed-duration treatment for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the first-line setting.

check_boxKey Events

• US FDA Approval for Calquence Combo

  The US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in combination with venetoclax for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the 1st-line setting.

• First All-Oral, Fixed-Duration Regimen

  This approval establishes the Calquence combination as the first all-oral, fixed-duration BTK inhibitor-based regimen in the US for 1st-line CLL, offering a 14-month treatment course.

• Strong Clinical Efficacy

  The approval is supported by positive results from the AMPLIFY Phase III trial, where 77% of patients treated with Calquence plus venetoclax were progression-free at three years, reducing the risk of disease progression or death by 35% compared to chemoimmunotherapy.

• Significant Market Opportunity

  CLL is the most common type of leukaemia in adults, with an estimated 18,500 people treated in the 1st-line setting in the US in 2024, representing a substantial market for this new treatment option.

auto_awesomeAnalysis

AstraZeneca has secured a significant US FDA approval for its Calquence (acalabrutinib) in combination with venetoclax, marking it as the first all-oral, fixed-duration regimen for adult patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the first-line setting. This approval is based on compelling data from the AMPLIFY Phase III trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard chemoimmunotherapy. The fixed-duration, all-oral nature of the treatment offers a new, convenient, and highly effective option for patients, potentially improving adherence and quality of life. This strengthens AstraZeneca's oncology portfolio and positions Calquence as a key player in the substantial US CLL market.